Most Clicked StoriesMore >


Performance-based deals on the table for specialty drugs

PCMA SmartBrief | Jul 24, 2015

UnitedHealth Group has reached an agreement for performance-based pricing of Gilead Sciences' hepatitis C drugs and is negotiating similar arrangements with makers of cholesterol-lowering PCSK9 inhibitors and therapies for rheumatoid arthritis and multiple sclerosis, according to Mark Thierer, leader of UnitedHealth's OptumRx unit. OptumRx's acquisition of Catamaran was completed Thursday. Bloomberg (07/23)


Cigna and Anthem expected to announce $48B merger deal

PCMA SmartBrief | Jul 23, 2015

Cholesterol drug priced at $14,600 a year

PCMA SmartBrief | Jul 27, 2015

Calif. measure would raise drug costs for all

PCMA SmartBrief | Jul 28, 2015

Report predicts 2020 drug trends

PCMA SmartBrief | Jul 28, 2015

Pharma is pressed to reveal costs behind high-priced drugs

PCMA SmartBrief | Jul 23, 2015

Consolidation of providers, drugmakers could follow deals by insurers

PCMA SmartBrief | Jul 27, 2015

Anthem agrees to acquire Cigna

PCMA SmartBrief | Jul 24, 2015

Centene poised to buy divested Medicare Advantage plans

PCMA SmartBrief | Jul 29, 2015

Approval of PCSK9 inhibitor puts focus on statin intolerance

PCMA SmartBrief | Jul 28, 2015


Find PCMA SmartBrief Issues by Date:





Sign up for PCMA SmartBrief



Designed specifically for PBM industry professionals, PCMA SmartBrief is a FREE, daily e-mail newsletter. It provides the the most relevant and actionable PBM industry news in a quick, easy to read format. Learn more